The global Regenerative medicine market is expected to reach USD 38.70 Billion by 2021 from USD 13.41 Billion in 2016 at a CAGR of 23.6% from 2016 to 2021. The major factor driving the growth of this market, are government and private funding to support the development of regenerative medicine, rising prevalence of chronic diseases and genetic disorders, increase in global healthcare expenditure, and rapid growth in the aging population.

The report segments this market based on types, therapy, application, and regions. Based on types, the Regenerative medicine market is segmented into cell-based products and acellular products. In 2016, cell-based products expected to dominate the global Regenerative medicine market. The key drivers includes the increasing awareness about stem cell therapy, growing funding for new stem cell lines, and development of advanced genomic methods for cell analysis.

Based on therapy, the Regenerative medicine market is segmented into cell therapy, gene therapy, tissue engineering, and immunotherapy. The cell therapy segment is expected to account for the largest share of this market, increasing funding from several agencies and private organizations for the research and development of cell therapies, growing inclination of the healthcare industry towards stem cell research, and increasing global awareness about the benefits of stem cell therapies.

By application, orthopedic & musculoskeletal disorders, dermatology, cardiology, diabetes, central nervous system diseases, and other applications. Oncology is expected to account the fastest growing market owing to increasing prevalence of cancer globally and rich product pipeline and increasing demand for cancer treatments.

Based on regions, the global Regenerative medicine market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of the market during the forecast period. Growth in this regional segment is driven by factors such as technological advancement in the Regenerative medicine and rising incidences of chronic diseases and aging population.

Key players in the Regenerative medicine market include Organogenesis Inc. (U.S.), Osiris Therapeutics, Inc. (U.S.), Vericel Corporation (U.S.), Stryker Corporation (U.S.), and NuVasive, Inc. (U.S.), Medtronic (Ireland), Acelity (KCI Concepts) (U.S.), Integra LifeSciences (U.S.), Cook Biotech Inc. (U.S.), and C.R. Bard (U.S.).